IRME
IR-Med Inc.
Set alert
0.00 USD 0.00 0.00%
0.0499 Day range 0.0499
0.001 52-week range 0.05
- YTD
- -93.00%
- 1 year
- -93.81%
- Open
- 0.0499
- Prev close
- 0.0021
- Mkt cap
- 231.13K
- Vol
- 594
- Avg vol
- 0
- EPS
- -0.04
- P/E
- 0.00
More statistics
- Low
- 0.0499
- High
- 0.0499
- Earnings
- Aug 13, 2024
Next earnings
Aug 13, 2024
Expected Aug 13, 2024. Consensus EPS estimate -0.01.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.01 | -0.01 | 0.00 | 0.00% |
| Aug 13, 2024 | Jun 1, 2024 | -0.01 | -0.01 | 0.00 | 0.00% |
| Aug 13, 2024 | Jun 1, 2024 | -0.01 | — | — | — |
| Nov 14, 2023 | Sep 1, 2023 | 0.00 | — | — | — |
| Nov 14, 2023 | Sep 1, 2023 | 0.00 | -0.02 | — | — |
| Aug 14, 2023 | Jun 1, 2023 | 0.00 | -0.02 | — | — |
News
- IR-MED and Dice Technologies Announce collaboration to Evaluate and Advance Pressure-Injury Prevention Platform in Japan
- IR-MED Ltd. Announces Launch of First-in-Human Clinical Trial of Its DiaSafe(TM) Device for Diabetic Foot Ulcer (DFU) Assessment
- IR-MED's Key Clinical and Media Milestones
- IR-MED Investor Update Letter - Sept-2025
- IR-MED Reports Positive Interim Results from U.S. Clinical Study of PressureSafe(TM) for Pressure Injury Assessment Across Diverse Skin Tones
- IR-MED Awarded $500,000 Grant from the Israel Innovation Authority to Advance AI-Powered DiaSafe(TM) Device for Diabetic Foot Ulcer Assessment
- IR-MED CEO Issues Letter to Shareholders: Expanding Our Platform and Presenting New Clinical Data from Israel and the U.S.
- Methodist Healthcare Adopts IR-MED's PressureSafe™ Device for Usability Study: Decision Support Device Aims to Reduce Substantial Healthcare Burden of Pressure Injuries
- IR-MED Appoints Ran Ziskind, Tech Entrepreneur, Growth Manager, and Inventor as Chief Executive Officer
- IR-MED Wins Prestigious Netty Award for Best Up-and-Coming Health Tech Company
Your note
Sign in to keep a note on IRME — it syncs with the Stock Master app.